Tumor cells in blood may indicate more aggressive breast cancer

April 08, 2003

TORONTO - If patients with breast cancer have tumor cells circulating in the blood, they may have a more dangerous form of the disease, according to a study by researchers at The University of Texas M. D. Anderson Cancer Center.

The results could lead to more tailored treatment that would spare some patients from the most potent chemotherapy and its toxic side effects.

The study, led by Massimo Cristofanilli, M.D., assistant professor of medicine in the Department of Breast Medical Oncology, was published in the Proceedings for the 2003 Annual Meeting of the American Association of Cancer Research, found that women who have tumor cells circulating in the blood have reduced survival compared to those without circulating tumor cells.

Until recently, doctors have not been able to reliably isolate circulating tumor cells. Within the last few years, several methods have been developed to label tumor cells with antibodies that can then be measured precisely, identifying even one tumor cell in a vial of blood, says Cristofanilli. In the current study, the scientists used an automated system developed by Immunicon Corp., Huntington Valley, Pa.

"We know that invasion and metastasis are the most life threatening aspects of cancer," says Cristofanilli. "To metastasize, cancer cells must leave the site of the primary tumor, travel through the blood and proliferate in a new site. If we discovered in a newly diagnosed patient that tumor cells are already in the blood, we would be aware that we are dealing with a more aggressive cancer that may require more aggressive treatment."

In the study, Cristofanilli and his colleagues studied 41 patients who had just been diagnosed with metastatic breast cancer and were about to begin treatment at M. D. Anderson. The scientists found circulating tumor cells in 24 of the 42 patients.

The women who had no circulating tumor cells had a median survival of more than 24 months, while those who had more than three circulating tumor cells survived an average of 13.6 months. Patients with more than 50 cells circulating had a median survival of only 3.8 months. Even more, says Cristofanilli, the presence of cancer cells in the blood predicted prognosis more accurately than the site of metastatic disease or the presence of estrogen receptor on the tumor cells, the scientists said.

"The general consensus is that if a tumor is estrogen receptor positive, it is considered slower growing and less aggressive," says Cristofanilli. "Our study indicates that if cancer cells are present in the blood, the cancer may be more aggressive, regardless of estrogen receptor status."

However, he emphasizes that the study included a relatively small number of patients and a larger study is needed. In addition, he would like to study the correlation of circulating tumor cells to how patients respond to various types of treatments.

"If you look carefully, patients who are considered to have similar disease by standard clinical criteria, may in fact have tumors that have quite different biological characteristics," he says. "Some patients might do better, no matter what treatment they receive. I would like to see circulating tumor status used prospectively to group patients for future clinical trials."
-end-
The study was funded by Immunicon Corp.

University of Texas M. D. Anderson Cancer Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.